A Phase I/II Study of Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for the Treatment of High-risk Hematologic Malignancies
Disease relapse remains the major cause of treatment failure in autologous stem cell
transplantation for patients with high-risk disease. Relapse after autologous transplant is
in part due to the persistence of residual cancer cells. Cellular immunotherapy using
activated autologous effector cells to recognize and kill tumor targets in a minimal disease
state after transplant is a strategy being explored to reduce relapse and improve survival.
We hypothesize that cytokine-induced killer (CIK) cell-based immunotherapy can reduce the
relapse rate after high-risk autologous stem cell transplantation by treating
post-transplant minimal residual disease.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
To document the toxicities of infusion of autologous CIK cells
Day 42 post autologous stem cell transplant
United States: Institutional Review Board
|Stanford University School of Medicine||Stanford, California 94305-5317|